Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC
Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage IA Non-small Cell Lung Cancer Presented as Ground-glass Nodules: Study Protocol of a Phase III, Randomized, Multi-center Trial (MELDSIG) in China
Sponsor: Tianjin Medical University Cancer Institute and Hospital
A NA clinical study on Lung Neoplasms and Lymph Node Excision, this trial is actively recruiting participants. The trial is conducted by Tianjin Medical University Cancer Institute and Hospital and has accumulated 6 data snapshots since 2022. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Recruiting NA
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
Oct 2023 — Jul 2024 [monthly]
Recruiting NA
-
Dec 2022 — Oct 2023 [monthly]
Recruiting NA
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Dec 2022 [monthly]
Not Yet Recruiting NA
▶ Show 1 earlier version
-
Dec 2020 — Jan 2021 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Tianjin Medical University Cancer Institute and Hospital
For direct contact, visit the study record on ClinicalTrials.gov .